Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.67 |
| ▸ | CLK2 | P49760 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | PIM1 | P11309 | 1/20 | 0.67 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435525 | 0.86 | CDC7 (0.70) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL5416571 | 0.84 | CDC7 (0.70) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL14338803 | 0.81 | CDK5 (0.47) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL2455100 | 0.81 | GSK3B (1.00) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL385584 | 0.80 | CDC7 (1.00) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL5429874 | 0.80 | GSK3B (0.56) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL14338804 | 0.79 | CDC7 (0.51) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL14350910 | 0.79 | GSK3B (0.54) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL5418891 | 0.76 | TRPA1 (0.51) | CDC7CLK2GSK3BCDK5DYRK1A | |
| SCHEMBL6756097 | 0.75 | TAS2R38 (0.60) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007124288-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293491-A1 | INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 | CDC7, CDC37, CDC73 | CDC7 1/4885CLK2 884/4885GSK3B 1106/4885 |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK2A2, CSNK1A1 | CDC7 532/4885CLK2 51/4885GSK3B 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.